doxylamine
Approved
Apr 7, 1948
Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic. Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects. Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women. — NCATS
Clinical trial activity
10 trials · 21 clinical orgs · 19 marketing orgs
Earliest trial started Jan 1, 2008 (NCT00614445)
Timeline
1940s
- Apr 7, 1948
Earliest FDA Approval
- Apr 7, 1948
Sanofi-Aventis — NDA Secondary Org
1970s
- Feb 13, 1978
Chattem — NDA Secondary Org
1980s
- Oct 8, 1985
Copley Pharmaceuticals — Marketing Organization
1990s
- Sep 18, 1996
Perrigo — Marketing Organization
2000s
- Aug 27, 2004
LNK International — Marketing Organization
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2008
Duchesnay Inc. — Earliest Phase 3 Sponsor(trial)
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
- Apr 8, 2013
Duchesnay Inc. — Marketing Organization
- Apr 8, 2013
Duchesnay Inc. — NDA Secondary Org
- Aug 19, 2016
Actavis — Marketing Organization
- Aug 19, 2016
Allergan PLC (2015) — Marketing Organization
- Dec 6, 2017
Par Pharmaceuticals — Marketing Organization
- Dec 6, 2017
Endo Pharmaceuticals — Marketing Organization
- Dec 6, 2017
Bristol-Myers Squibb — Marketing Organization
- Dec 6, 2017
PH HEALTH — Marketing Organization
2020s
- Jul 6, 2020
Mylan — Marketing Organization
- Jul 6, 2020
PHARMOBEDIENT — Marketing Organization
- Mar 1, 2022
AbbVie — Marketing Organization
- Aug 4, 2023
Bionpharma Inc — Marketing Organization
Indications
Approved for
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Combination products
bendectin
with pyridoxine
Also known as bonjesta, diclegis
Approval history
- approvedApr 7, 1948
Chemistry & pharmacology
SMILES
CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2- Mol. weight
- 270.3694 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Over the Counter
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaDoxylamine ↗
- NCATS95QB77JKPL ↗
- ChEMBLCHEMBL1627056 ↗
- ChEMBLCHEMBL1206050 ↗
- ChEMBLCHEMBL2111090 ↗
- ChEMBLCHEMBL1004 ↗
- ChEMBLCHEMBL1200392 ↗
- ChEMBLCHEMBL2107334 ↗
Also known as
- 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
- 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
- 2-dimethylaminoethoxyphenylmethyl-2-picoline
- 2-dimethylaminoethoxyphenylmethyl-2-picoline
- decapryn
- decapryn
- decapryn
- dossilamina
- dossilamina
- doxilamina
- doxilamina
- doxilminio
- doxilminio
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- doxylamine
- (+/-)-doxylamine
- doxylamine succinate
- doxylamine succinate
- doxylamine succinate
- doxylamine succinate
- doxylamine succinate
- doxylaminum
- doxylaminum
- doxy-sleep-aid
- doxy-sleep-aid
- n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
- n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
- phenyl-2-pyridylmethyl-beta-n,n-dimethylaminoethyl ether
- phenyl-2-pyridylmethyl-beta-n,n-dimethylaminoethyl ether
- unisom
- unisom
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06772974 | N/A | Jan 15, 2025 | Nawaz Sharif Medical College, University of Gujarat |
| NCT06342778 | Phase 1 | Feb 27, 2024 | Valenta Pharm JSC |
| NCT05498233 | N/A | Jul 11, 2022 | Valenta Pharm JSC |
| NCT04401384 | N/A | Jun 1, 2020 | Harbin maternal and child health care hospital, Hegang maternal and child health care hospital, Heilongjiang University of Traditional Chinese Medicine, Jiamusi maternal and child health care hospital, Jixi maternal and child health care hospital, Mudanjiang maternal and child health care hospital |
| NCT03905564 | Phase 1 | Jun 30, 2019 | Grunenthal |
| NCT03017430 | Phase 4 | Jan 1, 2014 | St. Petersburg Bekhterev Research Psychoneurological Institute |
| NCT01243437 | Phase 2 | Dec 1, 2010 | Centers for Disease Control and Prevention (CDC), Government of Uganda, Medical Research Council |
| NCT00857987 | Phase 3 | Apr 1, 2010 | Azidus |
| NCT00796315 | Phase 1 | Dec 1, 2008 | Consumer Healthcare Products Association, Procter and Gamble |
| NCT00614445 | Phase 3 | Jan 1, 2008 | Duchesnay Inc., Premier Research Group, The University of Texas, Dallas, University of Toronto |
Organizations
Research & Development (21)
Marketing (20)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | MKTG | Mar 1, 2022 |
| Actavis | For profit | MKTG | Aug 19, 2016 |
| Allergan PLC (2015) | For profit | MKTG | Aug 19, 2016 |
| Bionpharma Inc | For profit | MKTG | Aug 4, 2023 |
| Bristol-Myers Squibb | For profit | MKTG | Dec 6, 2017 |
| Chattem | For profit | NDA2 | Feb 13, 1978 |
| Copley Pharmaceuticals | For profit | MKTG | Oct 8, 1985 |
| Duchesnay Inc. | For profit | MKTG | Apr 8, 2013 |
| Duchesnay Inc. | For profit | NDA2 | Apr 8, 2013 |
| Endo Pharmaceuticals | For profit | MKTG | Dec 6, 2017 |
| LNK International | For profit | MKTG | Aug 27, 2004 |
| Mylan | For profit | MKTG | Jul 6, 2020 |
| PH HEALTH | For profit | MKTG | Dec 6, 2017 |
| PHARMOBEDIENT | For profit | MKTG | Jul 6, 2020 |
| Par Pharmaceuticals | For profit | MKTG | Dec 6, 2017 |
| Perrigo | For profit | MKTG | Sep 18, 1996 |
| Pfizer | For profit | NDA2 | — |
| Quantum Pharmaceutical | For profit | MKTG | — |
| Richardson Vicks Inc | For profit | NDA | — |
| Sanofi-Aventis | For profit | NDA2 | Apr 7, 1948 |